Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00839657 · ClinicalTrials.gov registry record · Phase 3
Clarification of Optimal Anticoagulation Through Genetics
A Phase 3 study, sponsored by National Heart, Lung, and Blood Institute (NHLBI).
- Completed
- Registry status
- Phase 3
- Development phase
- 1,015
- Enrollment target
NCT00839657: Completed Phase 3 study, sponsored by National Heart, Lung, and Blood Institute (NHLBI).
NCT00839657 is a Phase 3 study that has completed, run by National Heart, Lung, and Blood Institute (NHLBI). The registered enrollment target is 1,015 participants, above the 772-participant average among 15,282 other Phase 3 trials with a reported enrollment target (31% higher). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00839657, a Phase 3 study, has completed, sponsored by National Heart, Lung, and Blood Institute (NHLBI).
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 1,015 participants
- Enrollment target
Study Summary
Individuals taking warfarin often need frequent dose changes as the international normalized ratio (INR) gets too high or too low which could result in a higher risk of thromboembolism, bleeding and early discontinuation of a highly useful therapy. This study will compare two approaches to warfarin dosing to examine the utility of using genetic information for warfarin dosing.
Interventions
- BEHAVIORAL Genotype-guided dosing algorithm for warfarin
- BEHAVIORAL Clinical-guided dosing algorithm for warfarin
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 1,015 participants |
| Start Date | 2009-09 |
| Est. Completion | 2013-11 |
| Phase | Phase 3 |
What the finished NCT00839657 record still lists
NCT00839657 is an interventional study that assigns participants to a tested intervention. Its 1,015 participants enrollment target places it among the larger protocols in the corpus, above the 772-participant average among 15,282 other Phase 3 trials with a reported enrollment target (31% higher).
The record links to 0 conditions, and to 2 interventions - of which Genotype-guided dosing algorithm for warfarin is the first listed.
NCT00839657 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT00839657 about?
NCT00839657 is a clinical study titled "Clarification of Optimal Anticoagulation Through Genetics". Individuals taking warfarin often need frequent dose changes as the international normalized ratio (INR) gets too high or too low which could result in a higher risk of thromboembolism, bleeding and early discontinuation of a highly useful therapy. This study will compare two approaches to warfarin ...
What is the current status of trial NCT00839657?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 1,015 participants. The study started on 2009-09. Estimated completion is 2013-11.
What interventions are being tested in trial NCT00839657?
The interventions under investigation include: Genotype-guided dosing algorithm for warfarin (BEHAVIORAL), Clinical-guided dosing algorithm for warfarin (BEHAVIORAL).
Who is sponsoring clinical trial NCT00839657?
This trial is sponsored by National Heart, Lung, and Blood Institute (NHLBI), which has 501 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT00839657's enrollment target sits among peer trials
1,015 294th of 2000 higher than 1,707 of 2,000 other Phase 3 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 3 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT06146738 · 1,015 participants
The PALSUR-study: Palliative Care Versus Surgery in High-grade Glioma Patients (ENCRAM 2203)
- NCT06608823 · 1,016 participants · NA
ARTIST: Aortic Regurgitation Trial Investigating Surgery Versus Trilogy™
- NCT06549595 · 1,018 participants · Phase 3
A Study of Surovatamig (AZD0486) Plus Rituximab in Previously Untreated Follicular Lymphoma Patients
- NCT02178163 · 1,020 participants · NA
Comprehensive Genomic Analysis in Tissue Samples From Patients With Recurrent or Stage IV Non-small Cell Lung Cancer
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia